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At present time, there is uncertainty regarding whether influenza-like illness in healthy adults is best managed
by preventive efforts that use the trivalent influenza vaccine, administration of neuraminidase inhibitors at
the onset of illness, or recommendation of supportive care alone at the onset of illness. We conducted a cost-
effectiveness analysis that examined these 3 strategies for managing influenza-like illness. Vaccination with
inactivated trivalent vaccine would save approximately $25 per person while resulting in a net gain of ∼3.2
quality-adjusted hours relative to providing treatment with the neuraminidase inhibitor oseltamivir. A quality-
adjusted hour is a fraction of a quality-adjusted life-year, which is the equivalent of 1 year lived in perfect
health. Treatment with oseltamivir was associated with an incremental cost-effectiveness of approximately
$27,619 per quality-adjusted life-year gained relative to providing supportive care. Vaccination is cost-saving
relative to providing either treatment with oseltamivir or providing supportive care alone.
Influenza virus infections account for ∼30,000 deaths,
upward of 200,000 hospitalizations, and more than a
million ambulatory care visits and days of lost work in
the United States each year [1–4]. However, mortality
for adults who do not have diabetes, chronic lung dis-
ease, or heart disease is rare, and hospitalization rates
are much lower than they are among elderly individuals
or persons with chronic disease [4]. Nonetheless, un-
dervaccination of healthy adults almost certainly results
in morbidity and mortality when the virus is trans-
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mitted from healthy persons to persons who are highly
susceptible to influenza and its complications.
In the past, attempts to examine the economic costs
and benefits of influenza virus vaccination have been
limited to small vaccine trials, which have produced
equivocal results [5–9]. The primary limitations of
these studies were that the sample sizes were too small
to calculate rates of hospitalization; they were con-
ducted in particular geographic regions; and they only
collected data during 1–2 seasons. Because the inci-
dence of influenza is highly variable from region to
region and from year to year, it is not surprising that
some studies have demonstrated savings, whereas oth-
ers have demonstrated costs associated with vaccination
of healthy adults. To date, no comprehensive cost-ef-
fectiveness analysis has been conducted on vaccination
of healthy adults, in part because of data limitations.
Recently, morbidity and mortality data for influenza
virus infections have become available, which makes
such an analysis possible [4].
In 1999, two neuraminidase inhibitors, oseltamivir
and zanamivir, were introduced to international mar-
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Table 1. Assumptions used in deriving parameter estimates and justification.
Assumption Justification
No deaths would occur among healthy adults infected
with influenza virus infection
Few data were available [4]
10% of all patients with influenza-like illness will visit
a clinician within 48 h
This assumption was based on expert opinion and tested in a broad sensitivity
analysis
95% of clinicians will prescribe oseltamivir during
the therapeutic window of 48 h after the onset
of symptoms
This assumption was tested in a broad sensitivity analysis
95% of patients will be compliant with oseltamivir Efficacy data were obtained from randomized controlled trials [10–13]; compli-
ance with medications under real-world conditions is likely to be lower than
that observed under experimental conditions
The risk of hospitalization or death caused by influ-
enza will be reduced by 50% among persons tak-
ing oseltamivir
The observed reduction in secondary complications among subjects taking
oseltamivir in one randomized controlled trial was 50% [1]; a broad sensitiv-
ity analysis was conducted on this parameter
kets for use in the management of influenza virus infections
[10–13]. In studies published elsewhere, both agents were
shown to reduce the duration and severity of influenza infec-
tion, and to date, the oral preparation, oseltamivir, has not
been associated with serious side effects [10–14]. The Centers
for Disease Control and Prevention recommends that persons
who are at increased risk for influenza complications, such as
elderly individuals, receive the vaccine at the beginning of the
influenza season [14]; however, among healthy adults, there is
uncertainty regarding whether vaccination with the trivalent
influenza vaccine, treatment of influenza-like illness (ILI) with
neuraminidase inhibitors, or supportive care alone is the most
cost-effective strategy for reducing morbidity and mortality as-
sociated with influenza.
Universal vaccination requires administration of the vaccine
to persons who otherwise might not develop illness while ex-
posing them to the risks of experiencing minor side effects and
rare but serious events, such as Guillain-Barre´ syndrome [15].
Neuraminidase inhibitors are an attractive alternative to vac-
cination because they are administered only to persons who
develop illness, and like the influenza vaccine, they may de-
crease antibiotic consumption and secondary complications of
influenza. However, neuraminidase inhibitors are considerably
more expensive than the influenza vaccine, they attenuate
rather than prevent the illness, and they require administration
within 48 h after the onset of symptoms [10, 11, 16]. In this
study, we examine the costs and effectiveness of vaccination,
presumptive treatment with neuraminidase inhibitors, and sup-
portive care (rest, hydration, symptom relief, and medical care
as needed) for healthy adults with ILI aged 15–65 years.
METHODS
Overview and definitions. All healthy adults aged 15–65 years
residing in the United States in 1997 were entered into a decision-
analysis model as a hypothetical cohort. We adhered to the ref-
erence case guidelines of the Panel on Cost-Effectiveness in
Health and Medicine [17]. The analysis was conducted from the
societal perspective and includes all relevant costs except sec-
ondary transmission of the influenza virus. In our effectiveness
equations, we assumed that no deaths would occur, biasing the
analysis in favor of the supportive care option.
“ILI” is defined here as subjectively determined fever or a
measured temperature of 37.7C plus cough or sore throat
(the World Health Organization definition) [18]. Although
some studies that we included in our analysis used slightly
different definitions of ILI, we adjusted the data by means of
comparative parameters [9].
ILI is a constellation of upper and lower respiratory con-
ditions; therefore, it is associated with a high incidence rate of
illness; although ∼40%–50% of the civilian noninstitutionalized
population in the United States contracts a disease that meets
this symptomatic definition during the course of an influenza
season, the incidence rate of influenza virus infections is much
lower, averaging !10 cases per 100 persons per year [6, 9–12,
19, 20]. Many of the conditions that meet the technical defi-
nition of ILI, however, would probably not be mistaken for
influenza infection at a clinical examination. However, some
of these conditions may arise as a complication of a recent
infection with the influenza virus [11]. In our analysis, all stud-
ies (except 1 study in which the incidence of influenza was not
measured [5]) were conducted during an influenza season in
which the incidence rate of influenza virus infection was !10%.
Decision-analysis model. A decision-analysis model was
constructed using DATA, version 3.0 for Macintosh (TreeAge
Software), that examined 3 strategies: (1) vaccination of all
persons with the inactivated trivalent vaccine each influenza
season, (2) empirical treatment of persons developing ILI with
oral oseltamivir, 75 mg b.i.d. for 5 days, or (3) provision of
supportive care only. All assumptions of the model are listed
in table 1. The model was designed to obtain the probabilis-
tically weighted average cost and effectiveness of each strategy
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Table 2. Selected parameters included in the decision-analysis model.
Parameter Base High Low Source
Cost per patient, 1997 US dollars
Hospitalization, mean $5734.00 $7454.00 $4014.00 [21–24]
Guillain-Barre´ syndrome $100,800.00 $130,000.00 $70,000.00 [23]
Medical office visit for ILI $64.39 $84.00 $45.00 [6, 9]
5-Day course of oseltamivira $49.82 $53.00 $25.48 [25]
Influenza vaccine, administration, and patient time $12.57 $16.75 $6.99 [26–28]
Over-the-counter medications for ILI $8.48 $11.03 $5.94 [9, 25]
Caregiving costs for persons with ILI $53.56 $69.62 $37.49 [29]
Reduced transportation and environmental costs for ILI
Money saved when bed bound with ILI $19.49 $28.25 $10.72 [26–28]
Money spent visiting doctor $6.96 $10.09 $3.83 [26–28]
Probability of
Development of ILI 0.49 0.50 0.21 [6, 9, 12, 15]
Compliance with oseltamivir 0.95 1 0.5 Assumed
Guillain-Barre´ syndrome 1  10-6 9  10-6 0.5  10-6 [15]
Hospitalization for influenzab 0.00024 0.024 0.00018 [4, 30]
Proportionate improvement, oseltamivir 0.213 0.248 0.18 [10–14]
Physician prescribing oseltamivir within 48 h 0.95 1 0.1 Assumed
Medical visit for ILI, supportive care arm 0.75 0.58 0.91 [6, 9]
Medical visit for ILI, treatment arm 0.695 0.54 0.91 [6, 9, 12]
Medical visit for ILI, vaccination arm 0.38 0.23 0.53 [6, 9]
Medical visit related to side effectsc 0.01 0.05 0 [10–14, 6, 9]
Health-related quality of life 0.61 0.79 — [31]
NOTE. ILI, influenza-like illness.
a Dosage was 75 mg b.i.d. Cost was deflated to $1997 using average medical inflationary rate, 1994–1997.
b Among persons ill with ILI.
c The probabilities of side effects from influenza vaccination and oseltamivir were approximately equivalent.
by use of the inputs listed in table 2. Each strategy was associated
with a similar pathway of events: (1) the probability of illness,
(2) the probability of a medical visit (including the probability
of illness secondary to a primary influenza virus infection), (3)
the probability of receiving antibiotics for secondary illnesses,
(4) the probability of receiving over-the-counter medications,
and (5) the probability of hospitalization. In the treatment and
vaccination arms, the probability of side effects was also in-
cluded, as were the costs of each treatment.
Costs. The costs associated with hospitalization caused by
influenza virus infection and its complications were obtained
from the 1997 Healthcare Cost and Utilization Project–3, a
weighted database that includes information about approxi-
mately one-half of all hospital discharges in the United States
[21]. Because hospital charges may not reflect the true societal
costs of hospitalization, charges were converted to costs by use
of cost-to-charge ratios derived from the Medical Provider
Analysis and Review system of the Health Care Finance Ad-
ministration [22]. Costs associated with ambulatory medical
care were obtained from the medical literature [5, 9]. The cost
of syringes preloaded with influenza vaccine, oseltamivir, and
over-the-counter medications were obtained by use of average
wholesale prices from the Red Book and the medical literature
[5, 9, 25]. The cost of vaccination included 30 min of patient
time ($8.37) and 5 min of time for administration by a reg-
istered nurse ($1.70) [26, 27]. We estimated over-the-counter
drug consumption and costs by use of weighted mean values
from randomized controlled trials published in the medical
literature [9, 11].
Transportation use was estimated on the basis of data from
the Bureau of the Census [28]. Costs associated with travel to
work or school were adjusted for the number of persons car-
pooling, biking, or walking [28]. Persons who were ill with an
ILI were assigned 2.8 days of bed rest [29]; thus, they were not
expected to incur costs associated with traveling to work during
that time period.
Caregiver support costs were obtained from the medical lit-
erature, the Bureau of Labor Statistics, and the Bureau of the
Census [26, 27]. Patient time included time spent in transit to
a medical clinic or hospital, in addition to the time spent re-
ceiving ambulatory care or hospital services. All costs were
adjusted to 1997 US dollars.
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Table 3. Costs, effectiveness, and incremental cost-effectiveness of the 3 interventions










Support $66.39 0.00779 — — —
Treatment $77.99 0.00821 $11.60 0.00049 $27,619
Vaccination $52.92 0.00853 ($25.07)c 0.00037 Savingsd
NOTE. All outcomes occur within 1 year; thus, no discounting is applied. Values are rounded.
a The incremental change in cost or effectiveness is calculated by subtracting the cost or effectiveness of
an intervention from the cost or effectiveness of the next-most-effective intervention.
b The incremental cost-effectiveness ratio is calculated by dividing the incremental cost of an intervention
by the incremental effectiveness of that intervention.
c Parentheses indicate savings.
d It is not possible to calculate a cost-effectiveness ratio for cost-saving interventions.
Probabilities. The mean rate of hospitalization as a result
of influenza infection or its complications was obtained from
the medical literature [4, 30]. These studies encompass 19 years
of data for healthy persons aged 15–65 years. From the medical
literature, we obtained the probabilities of the following: (1) side
effects from vaccination or oseltamivir [10–14], (2) medical visits
in vaccinated and unvaccinated persons [5, 9], (3) Guillain-Barre´
syndrome [15] resulting from influenza vaccination, and (4) sec-
ondary bacterial infections arising as a result of influenza [11].
The efficacy of the vaccine in the prevention of ILI [6, 9] and
influenza virus infection [9] was adjusted on the basis of an
estimate that the vaccine would be poorly matched to circulating
influenza strains approximately once every 10 years [9]. Data
obtained from the general population in the United States were
adjusted by accounting for the proportion of the population in
the United States that was vaccinated in 1997 [32] and the efficacy
of the trivalent influenza vaccine [9, 19] so that these rates would
reflect those of an unvaccinated cohort.
The range of incidence rates for ILI during an average in-
fluenza season were determined by the mean rate from a num-
ber of prospective studies [6, 9, 12, 20]. No data were available
on the probability of a medical visit for persons treated with
oseltamivir. To estimate this probability, we adjusted the rate
of ambulatory visits in unvaccinated, untreated persons by re-
ducing the expected number of medical visits by the number
of secondary complications averted in persons treated with
oseltamivir. The proportionate reduction in the duration of
influenza-like symptoms (21.3%) was used to apportion hours
of ill time and healthy time among persons treated with os-
eltamivir [11].
Quality-adjusted life-years. We calculated quality-ad-
justed life-years (QALYs) under the assumption that no deaths
would occur among healthy adults. The Quality of Well-Being
(QWB) scale was used to estimate the health-related quality of
life (HRQL) score for persons with ILIs [31]. The QWB scale
converts data pertaining to mobility, physical activity, and social
dimensions of a disease, along with information about the
symptoms and problems a disease produces, to an HRQL score.
The Years of Healthy Life (YHL) measure was used to assess
the baseline health status of persons in the United States [33].
Sensitivity analysis. Baseline parameter estimates and the
range of plausible values for each estimate are listed in table
2. All variables were tested for their influence on the model by
a multivariate sensitivity (“tornado”) analysis. Variables that
demonstrated sufficient influence on the rank order of the cost
or effectiveness of each intervention were then tested in 1-way
and, where appropriate, bivariate sensitivity analyses. All as-
sumptions were tested by use of broad 1-way sensitivity anal-
yses. To test effectiveness parameters, we ran the model with
an HRQL score obtained from the Health Utilities Index (HUI)
mark 2 and varied the baseline health state of the cohort by
means of the YHL measure [33, 34].
We also conducted a Monte Carlo simulation under the as-
sumption that all variables would be triangular in distribution.
The triangular distribution is a probability distribution in which
the baseline value of a parameter is assigned the highest prob-
ability of occurrence and the extreme high and low values of
a parameter are assigned the lowest probability of occurrence.
The probability of observing a value in between the baseline
value and either the high or low value assigned to a variable
is linearly interpolated.
RESULTS
Table 3 lists the average cost per person and effectiveness of
the 3 interventions under study. The decision-analysis model
predicted that the cost of vaccinating persons aged 15–65 years
(approximately $53 per person) would be lower than the cost
of treatment with oseltamivir (approximately $78 per person)
or supportive care (approximately $66 per person) when the
incidence of ILI is 49 cases per 100 persons. Vaccinating all
persons aged 15–65 years would result in a net gain of ∼0.00037
QALYs or 3.2 quality-adjusted hours and savings of approxi-
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Figure 1. One-way sensitivity analysis of the incidence of influenza-
like illness (ILI). As the incidence of ILI increases, the per-person cost of
the vaccination arm () increases less rapidly than the cost of supportive
care () or treatment (H17009) with oseltamivir, resulting in lower overall
costs for vaccination than for the other strategies when the incidence
of ILI is 124.2 cases per 100 persons. The base case rate of ILI is 49%.
mately $25 per person relative to providing treatment during
an average influenza season.
Vaccinating all persons aged 15–65 years would result in a
net gain of ∼0.00074 QALYs or 6.5 quality-adjusted hours and
savings of approximately $13 per person relative to providing
supportive care during an average influenza season (data not
shown). Treatment with oseltamivir was associated with an in-
cremental cost-effectiveness ratio of $27,619 per QALY relative
to supportive care.
When tested for costs, the model was most sensitive to the
following variables, in descending order of sensitivity: incidence
of ILI, transportation costs, caregiver costs, the cost of a medical
visit in the vaccination arm, and the cost of the influenza vac-
cine. Vaccination remained the dominant strategy when each
of these variables was tested over the range of plausible values
of each parameter (table 2).
The incidence of ILI was the major determinant of the pre-
dicted cost savings. When the incidence of ILI was greater than
∼24.2 cases per 100 persons, vaccination was cost-saving rel-
ative to providing only supportive care (figure 1).
The decision model was robust with respect to changes in
the plausible values of all variables. On the basis of a 2-way
analysis of the incidence of ILI and vaccine efficacy, we estimate
that vaccination would only be expected to be associated with
costs approximately once every 10 years. None of the assump-
tions made in the analysis affected the dominance of the vac-
cination strategy when tested over a broad range of values.
When the HUI was substituted for the QWB scale to calculate
QALYs, the effectiveness of the supportive-care arm increased
by 10%, the treatment arm increased by 8%, and the vacci-
nation strategy increased by 6%. The Monte Carlo analysis
predicted that vaccination would be the cost saving in ∼75%
of all trials; provision of supportive care would be dominant
in ∼15% of trials.
It is feasible that future generic versions of neuraminidase
inhibitors will be significantly less expensive than are current
formulations. If a 5-day course of oseltamivir were made avail-
able for less than approximately $15.00, it would be a cost-
saving intervention relative to supportive care. Vaccination
would be slightly less costly than oseltamivir overall, even if
this medication were free.
The costs of vaccination in this analysis only included the
costs of the influenza vaccine, medical supplies, vaccine ad-
ministration, and patient time because our recommendations
were to promote vaccination in the workplace or as part of a
medical visit for reasons unrelated to influenza infection. If all
patients were to visit their doctors specifically to receive the
influenza vaccine, vaccination would be associated with an in-
cremental cost-effectiveness ratio of $31,081 relative to sup-
portive care.
DISCUSSION
Vaccinating persons aged 15–65 years with the inactivated tri-
valent influenza vaccine is cost saving relative to treating symp-
tomatic persons with oseltamivir or providing supportive care.
Vaccination of all persons in this age group would save ap-
proximately $25 and 0.0004 QALYs per person relative to pro-
vision of treatment during an average influenza season (table
3). Treating only those persons who developed an ILI with
oseltamivir would cost approximately $27,619 per QALY gained
relative to supportive care.
Because our initial analysis demonstrated that vaccination
was dominant even when tested over a wide range of plausible
values in a sensitivity analysis, we chose not to model the pos-
sible effects of herd immunity produced by vaccinating all per-
sons aged 15–65 years, neuraminidase inhibitor–resistant in-
fluenza viruses, or laboratory testing for the influenza virus.
Inclusion of each of these effects would only increase costs in
the oseltamivir arm while increasing savings of both dollars
and lives with vaccination.
Our study was limited by a number of factors. First, we had
difficulty in adjusting data to the World Health Organization
definition of ILI [18], which is a constellation of symptoms
not consistently defined in the medical literature. Although the
use of this symptom-based definition allowed us to improve
the model of the diagnosis, treatment, and prevention of in-
fluenza infection in the real world, it affected the comparability
of the different parameters we used.
We also had difficulty in obtaining a precise incidence rate
for ILI in unvaccinated persons. Although the incidence rate
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of influenza virus infections varies 5%–27% between different
geographic regions and different studies [9, 19, 20, 35], the
incidence rates of ILI reported in the medical literature are
generally much higher [6–9, 12, 19, 20], because ILI encom-
passes a broader range of infectious agents. Nonetheless, vac-
cination remained cost saving, relative to supportive care, pro-
vided the incidence rate of ILI was 124 cases per 100 persons,
which is well below rates quoted in the medical literature.
No data were available on the efficacy of oseltamivir in re-
ducing the consumption of medical resources or mortality
caused by influenza virus infections. We assumed that medical
use would be reduced in proportion to reductions in the rate
of secondary illness among persons treated with oseltamivir.
In a retrospective cohort study of influenza-associated mor-
tality in women [4], 2 excess deaths occurred per 100,000
person-months in healthy subjects; however, this rate was not
significantly higher than was the rate observed during the
peri-influenza season. Although secondary transmission of the
influenza virus from healthy adults to persons at risk for death
would likely be reduced by vaccination, we were unable to
obtain a reliable estimate of the extent to which this interven-
tion would reduce mortality nationwide. Because the vacci-
nation strategy was found to be dominant and because inclu-
sion of deaths averted in our analysis would only have
strengthened these findings, we chose to exclude deaths from
the analysis altogether.
Finally, we used the QWB scale to derive the HRQL for
persons with ILI. This instrument is based on category scaling
measurements—a method that does not technically produce
utilities [31]. We chose this instrument rather than the HUI
[34] because the health dimensions it incorporates are similar
to those produced by ILI. Because the methods used to obtain
utilities for the QWB scale differ from those used in other
instruments, variation in HRQL values can occur [33]. Sub-
stituting the HUI score for the QWB score did not affect the
relative dominance of vaccination, because this strategy is con-
siderably more effective than oseltamivir at reducing the total
number of days subjects spend with an ILI. However, the use
of the HUI score did differentially affect the effectiveness of
each intervention under study.
HRQL scores typically assume a value from 0 to 1.0, with 0
being equivalent to death and 1.0 equivalent to perfect health.
Although our hypothetical cohort consisted of adults without
chronic lung disease, chronic heart disease, or diabetes mellitus,
the cohort would not be expected to be in perfect health. The
QWB scale was designed to assign a value to a particular disease,
and it cannot be used to estimate the overall health of a pop-
ulation. For this reason, we used the YHL measure to estimate
the overall health of our cohort for persons who did not develop
an ILI and for persons who recover from an ILI.
Cost-effectiveness analyses associated with cost savings are
rare and typically include interventions targeted toward high-
risk populations, such as pneumococcal vaccination to prevent
bacteremia in elderly populations, or presumptive treatment of
parasitosis in immigrant populations [36, 37]. Although less
cost-effective than vaccination, neuraminidase inhibitors
[10–14, 38, 39] may be a cost-effective modality for preventing
morbidity and mortality in unvaccinated persons who present
to medical practitioners with an ILI. Of the currently available
management strategies to address influenza infection in the
healthy adult population in the United States, vaccination is
the most cost-effective method to decrease health care costs,
morbidity, and mortality, and it should be strongly considered
for all persons without contraindications to the vaccine.
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